Another Treatment for Type 1 Diabetes

In children with newly diagnosed type 1 diabetes, injections with the autoantigen glutamic acid decarboxylase slowed insulin secretion without significant adverse effects.

Autoantigens induce immunologic tolerance and have been shown to prevent type 1 diabetes in mice. In a double-blind clinical trial, Swedish investigators examined the safety and efficacy of the autoantigen glutamic acid decarboxylase (GAD) — a major autoantibody in patients with type 1 diabetes. Seventy patients (age range, 10–18 years) with recent-onset (within 18 months) type 1 diabetes, fasting C-peptide levels >0.1 nmol/L, and GAD antibodies were randomized to receive daily doses of insulin plus two injections (on days 1 and 30) of either recombinant human GAD-alum or alum alone.

The primary outcome of change in fasting C-peptide levels between baseline and 15 months did not differ significantly in the two groups (levels decreased gradua…

Reviewing Author

Howard Bauchner, MD

Disclosures

Grant / research supportHuman Resources and Services Administration; NIH; NIH-NHLBI; USDA; GlaxoSmithKline

Editorial boardsArchives of Disease in Childhood (Editor-in-Chief)

Howard Bauchner, MD

Disclosures

Grant / research supportHuman Resources and Services Administration; NIH; NIH-NHLBI; USDA; GlaxoSmithKline

Editorial boardsArchives of Disease in Childhood (Editor-in-Chief)

Another Treatment for Type 1 Diabetes

Topics

Reviewing Author